December 3, 2009 — The Cervarix vaccine, manufactured by GlaxoSmithKline, provides a high level of long-term protection against human papillomavirus (HPV) types 16 and 18. According to new data ...

WASHINGTON (Reuters) - GlaxoSmithKline Plc's bid to sell its Cervarix cervical cancer vaccine in the United States faced further delay on Tuesday and the company recalled a batch of the vaccine in ...

GlaxoSmithKline announced the results of a Phase III study of its HPV vaccine, Cervarix, which showed that two doses of the vaccine in girls aged 9 to 14 years provide an immunogenicity matching the ...

September 11, 2009 — A second vaccine against human papillomavirus (HPV) for the prevention of cervical cancer — GlaxoSmithKline's Cervarix — has been recommended for approval in the United States; ...

The pursuit to become the top-selling cervical cancer vaccine intensified last week as GlaxoSmithKline submitted its Biologics License Application (BLA) for Cervarix with the FDA. Cervarix is being ...

Two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule, research shows. Since high coverage and compliance rates can be ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. The Centers for Disease Control and Prevention’s Advisory Committee on ...

GlaxoSmithKline's Cervarix may have been the first HPV shot approved in mainland China, but Merck's Gardasil now has an opening to gain the lead. Cervarix hasn't launched yet in the country, and as of ...

NEW YORK (Reuters) - GlaxoSmithKline Plc's cervical cancer vaccine Cervarix should eventually secure a 50 percent market share, despite being second to market, the group's chief executive said on ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. For the record: An earlier version of this story and its headline ...

Amanda Steele first noticed a change in her daughter Carly last summer. The normally exuberant 13-year-old had lost all of her energy. Whereas normally she would have spent her days outside on the ...

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.